Finance, Procurement and Contracting

Financial Performance Report: Month 3

Jason Dorsett: Chief Finance Officer

Accessible Information Standard notice: We are committed to ensuring that everyone can access this document as part of the Accessible Information Standard. If you have any difficulty accessing the information in this report, please contact us.

Executive Summary

Oxford University Hospitals
NHS Foundation Trust

Overall Monthly Position

The plan in month 3 was for a £3.9m deficit. the Trust achieved a £1.8m deficit which is favourable to plan by £2.1m. The underlying deficit at month 3 is £9.1m. All commentary below removes passthrough type effects which are explained in more detail later in the report.

Income was £6.8m better than plan with estimated NHS clinical income +£3.9m (based in M1 and M2 coded activity per day extrapolated to M3) and other income +£3.1m (£1.7m for hosted services and £1.0m R&D, both offset by expenditure, £0.4m on Education and Training income).

Pay was £0.7m worse than plan. This is driven by an adverse variance of £0.8m in R&D (offset by income). Non-recurrent savings from ~370 vacancies are more than offsetting a £0.5m overspend on bank.

Non-pay is £3.6m worse than plan. The driving variances are in HIOTV and R&D of £1.9m (offset by income) and £2.3m adverse in Trust reserves (driven by £1.7m shortfall on non-recurrent CIP). Offsets in PFI an energy reduced the overspend.

CIP was £0.9m adverse to plan predominantly in recurrent non-pay savings. The rate of CIP identification and delivery will need to improve rapidly in ALL divisions to avoid further spending control.

Cash

Cash was £7.2m at month 3 which was £3.6m above plan. Cash is now close to plan after the completion of the year end creditor unwinding, with a slightly higher June balance due to in-year 26/27 capital spend being behind plan, this is timing and not a permanent difference. The cash plan for 2026/27 suggests that the pressure on cash will return, now the timing issues have unwound from 2025/26.

Capital

Gross capital expenditure to June was £9.4m against a plan of £22.1m. There were lower than planned expenditure on prior-year overruns and little expenditure in month on new business. Some cost pressures realised from prior year may require mitigatory measures in the forward delivery plan.

MRC

MRC are £1.0m **favourable** to plan in month 3, driven by backdated Q1 activity over performance of £1.0m – mainly Elective work in Cardiology. The division attributes a £0.8m over-spend on higher temporary staff spend to vacancies but needs to increase control. It has planned limited CIPs to date and this must improve rapidly.

NOTSSCaN

NOTTSCaN are £1.2m **favourable** to plan in month 3, driven by backdated Q1 activity over performance of £1.0m – from Neurosciences (£0.6m) and Paediatrics (£0.4m). Non-recurrent efficiencies of £2.9m pay and £1.8m of non-pay, including non-recurrent underspends and vacancies.

SUWON

SUWON are £0.7m **favourable** to plan in month 3, driven by backdated Q1 activity over performance of £0.7m - . £0.5m in Oncology. Underachieved non pay CIP of £0.7m is partly offset by other income benefit of £0.5m.

CSS

CSS are **on plan** in month 3, driven by backdated Q1 activity over performance of £0.5m - Radiology £0.7m. The division needs to increase plans for future CIP delivery.

Non-Clinical

Non-Clinical (inc. Corp, R&D, Education and Estates) is reporting a **favourable** variance of £0.7m in month 3 (3.5% on a cost of £20.4m) largely due to utilities and rates underspends of £0.4m.

Central

Central budgets are £1.6m **adverse** to plan at month 3, due primarily to a £1.7m shortfall on non-recurrent CIP offset by a non-recurrent £0.4m PFI benefit.

Income and Expenditure Position: Trustwide Overview

Oxford University Hospitals
NHS Foundation Trust

Source: Budget in Finance Ledger.

Financial Summary OUH	IN MONTH 3				YEAR TO DATE				Full Year	Full Year		
£000s	Plan	Actual	Var £	Var %	Plan	Actual	Var £	Var %	Plan	Forecast	Var £	Var %
Activity Income	109,825	113,681	3,856	3.5%	326,327	330,911	4,584	1.4%	1,321,459	1,321,459	0	0.0%
Pass Through(Income)	20,550	25,353	4,803	23.4%	64,799	65,442	643	1.0%	259,197	259,197	0	0.0%
PP, Overseas &RTA Income	1,563	1,393	(170)	(10.8%)	4,689	3,905	(783)	(16.7%)	18,880	18,880	0	0.0%
Other Income	15,905	19,000	3,095	19.5%	49,526	48,657	(870)	(1.8%)	192,500	192,500	0	0.0%
Income Total	147,844	159,427	11,584	7.8%	445,341	448,915	3,574	0.8%	1,792,036	1,792,036	0	0.0%
Staff	(82,114)	(82,472)	(358)	(0.4%)	(248,725)	(245,869)	2,856	1.1%	(956,319)	(956,319)	0	0.0%
NHSP	(3,333)	(3,792)	(459)	(13.8%)	(10,075)	(11,972)	(1,897)	(18.8%)	(39,460)	(39,460)	0	0.0%
Agency	(239)	(168)	70	29.5%	(840)	(680)	160	19.0%	(2,988)	(2,988)	0	0.0%
Pay Total	(85,685)	(86,433)	(747)	(0.9%)	(259,641)	(258,521)	1,119	0.4%	(998,767)	(998,767)	0	0.0%
Clinical Supplies & Services (Excl Pass Through)	(11,358)	(13,571)	(2,213)	(19.5%)	(32,117)	(37,454)	(5,337)	(16.6%)	(132,087)	(132,087)	0	0.0%
Pass Through(NonPay)	(20,550)	(25,353)	(4,803)	(23.4%)	(64,799)	(65,442)	(643)	(1.0%)	(259,197)	(259,197)	0	0.0%
Drugs (Excl Pass Through)	(5,410)	(5,650)	(240)	(4.4%)	(15,038)	(15,768)	(730)	(4.9%)	(60,474)	(60,474)	0	0.0%
Premises and Fixed Plant	(9,287)	(9,042)	245	2.6%	(28,045)	(28,292)	(247)	(0.9%)	(112,404)	(112,404)	0	0.0%
Other Non-Pay	(10,849)	(12,181)	(1,332)	(12.3%)	(34,800)	(31,592)	3,208	9.2%	(122,908)	(122,908)	0	0.0%
Non-Pay Total	(57,454)	(65,797)	(8,343)	(14.5%)	(174,799)	(178,549)	(3,750)	(2.1%)	(687,071)	(687,071)	0	0.0%
EBITDA	4,704	7,198	2,494	53.0%	10,901	11,845	944	8.7%	106,198	106,198	0	0.0%
Capital and Financial Charges	(8,614)	(9,017)	(403)	(4.7%)	(26,694)	(27,341)	(648)	(2.4%)	(106,149)	(106,149)	0	0.0%
Control Total	(3,910)	(1,819)	2,091	53.5%	(15,793)	(15,497)	296	1.9%	48	48	0	0.0%

	IN MONTH 3			
WTE	Plan	Actual	Variance	Var %
Staff	14,124.4	13,351.6	773	5.5%
NHSP	216.4	606.1	(390)	(180.1%)
Agency	5.4	20.2	(15)	(270.6%)
Total WTE	14,346.2	13,977.8	368	2.6%

Trust

Month 3 saw a £1.8 deficit vs a £3.9m planned deficit. The plan for the full year remains a breakeven position. The non-recurrent items included in the month 3 position total £5.0m (including vacancies being held non-recurrently) which means the Trust's underlying position is a deficit of circa £9.1m at month 3. Worked wte's are 368 under budget plan at month 3.

Income

Income is £11.6m favourable to plan at month 3, but removing passthrough and similar items it is £4.1m better than plan. Commissioning activity has a positive variance of £3.9m based on flex information showing over performance for month 2, which has been extrapolated to month 3. Passthrough (+£4.8m), R&D (+£1.0m) and HIOTV (+£1.7m), over performed offset by costs.

Pay

Pay is £0.7m adverse to plan at month 3. This includes an adverse variance of £0.8m in R&D (offset by income, no associated wte). The Trust is 368 wte below plan, with 773 vacancies offset by NHSP (390 wte) and agency (15 wte). Vacancies have been held during the recruitment controls (estimated £2.2m benefit this month), but we judge this to be non-recurrent as the posts have not been removed. Note there is a misalignment between the establishment in ESR and in the ledger with ESR showing unbudgeted posts. Finance and People functions are working to resolve this.

Non-Pay

Non pay is £8.3m adverse to plan at month 3, but removing passthrough and similar items it is £1.6m adverse to plan. This is driven by £1.7m shortfall on non-recurrent CIP. The clinical supplies overspend is not yet fully analysed between CIP under-delivery, activity driven pressures and other factors. These are partially offset by PFI deductions of £0.4m and utilities underspends of £0.2m.

Income and Expenditure: Divisional Positions

Source: Finance Ledger.

Oxford University Hospitals
NHS Foundation Trust

	Division Financial Summary OUH	IN MONTH 3				YEAR TO DATE				Full Year	Full Year		
	£000s	Plan	Actual	Var £	Var %	Plan	Actual	Var £	Var %	Plan	Forecast	Var £	Var %
Clinical	Medicine Rehabilitation and Cardiac	8,379	9,331	951	11.4%	25,126	24,486	(640)	(2.5%)	107,086	107,086	0	0.0%
	Neurosciences Orthopaedics Trauma Specialist Surgery Chil	7,512	8,695	1,183	15.7%	23,683	23,858	174	0.7%	111,460	111,460	0	0.0%
	Surgery Women and Oncology	11,896	12,622	726	6.1%	30,591	29,211	(1,379)	(4.5%)	128,870	128,870	0	0.0%
	Clinical Support Services	(8,238)	(8,140)	98	1.2%	(25,612)	(25,484)	128	0.5%	(95,803)	(95,803)	0	0.0%
Non-Clinical	Corporate	(12,228)	(12,287)	(59)	(0.5%)	(36,756)	(37,045)	(289)	(0.8%)	(146,390)	(146,390)	0	0.0%
	Estates	(12,382)	(12,045)	337	2.7%	(38,626)	(36,654)	1,972	5.1%	(154,498)	(154,498)	0	0.0%
	Education and Training	3,973	4,467	494	12.4%	11,902	13,140	1,237	10.4%	47,952	47,952	0	0.0%
	Hosted Services DIV	0	1	1	715.2%	0	(5)	(6)	(2,305.3%)	1	1	0	0.0%
	Research and Development	200	150	(50)	(24.8%)	600	533	(67)	(11.2%)	2,400	2,400	0	0.0%
Tech	Operating Expenses	(4,157)	(3,860)	297	7.2%	(13,189)	(13,302)	(113)	(0.9%)	(51,996)	(51,996)	0	0.0%
	Trustwide Reserves	1,135	(753)	(1,887)	(166.3%)	6,488	5,767	(721)	(11.1%)	50,966	50,966	0	0.0%
	Total, by Directorates	**(3,910)**	**(1,819)**	**2,091**	**53.5%**	**(15,793)**	**(15,497)**	**296**	**1.9%**	**48**	**48**	**0**	**0.0%**

Clinical

Clinical divisions are £1.7m off plan year to date.

SUWON are the most significant at £1.4m off plan, driven by in tariff drugs activity (£0.7m, of which £1.2m is in Oncology offset with £0.5m in Gastroenterology) and underachieved non pay CIP of £1.5m, offset by £0.7m above plan on activity income.

MRC are £0.6m off plan, driven by £0.3m of non-recurrent industrial action costs, unachieved CIP £0.2m and temporary pay £0.1m.

NOTSSCaN are £0.2m favourable to plan. Efficiencies have over-achieved year to date by £0.7m but by non-recurrent means.

CSS are £0.1m favourable to plan, driven by activity above plan £0.5m (Radiology £0.7m) and underspends in clinical supplies (£0.8m), offsetting CIP delivery shortfall.

Non-Clinical

Non-Clinical areas are £2.8m better than plan year to date.

Estates Division £2.0m better than plan, from PFI operating underspends (£0.7m) and utilities (FY impact under review) (£1.4m).

Corporate Division £0.3m off plan, driven by RTA income £0.2m off plan.

Education £1.2m favourable variance due to increase in funding for 2026/27.

R&D are £0.1m off plan.

Central

Central budgets are £1.2m better than year to date, due primarily to a £1.6m non-recurrent PFI benefit in non-pay.

The Operating Expenses Division is £0.1m adverse variance including £0.6m overspend on finance costs, offset within non-pay.

I&E: Divisional Position MRC

Oxford University Hospitals
NHS Foundation Trust

Financial Summary N4EMTA £000s	IN MONTH 3 Plan	IN MONTH 3 Actual	IN MONTH 3 Var £	IN MONTH 3 Var %	YEAR TO DATE Plan	YEAR TO DATE Actual	YEAR TO DATE Var £	YEAR TO DATE Var %	Full Year Plan	Full Year Forecast	Var £	Var %
Activity Income	29,326	30,358	1,032	3.5%	86,770	87,803	1,032	1.2%	347,866	347,866	0	0.0%
Pass Through(Income)	5,572	7,368	1,796	32.2%	19,574	20,522	948	4.8%	78,295	78,295	0	0.0%
PP, Overseas &RTA Income	558	638	80	14.3%	1,675	1,924	249	14.9%	6,700	6,700	0	0.0%
Other Income	376	369	(7)	(1.7%)	1,303	1,016	(288)	(22.1%)	5,214	5,214	0	0.0%
Income Total	35,832	38,733	2,901	8.1%	109,323	111,265	1,942	1.8%	438,074	438,074	0	0.0%
Staff	(17,741)	(17,173)	568	3.2%	(53,518)	(51,955)	1,563	2.9%	(208,486)	(208,486)	0	0.0%
NHSP	(322)	(1,028)	(706)	(219.1%)	(1,031)	(3,640)	(2,609)	(253.0%)	(3,914)	(3,914)	0	0.0%
Agency	(8)	(77)	(70)	(888.5%)	(23)	(255)	(232)	(986.8%)	(94)	(94)	0	0.0%
Pay Total	(18,071)	(18,279)	(208)	(1.1%)	(54,573)	(55,851)	(1,278)	(2.3%)	(212,493)	(212,493)	0	0.0%
Clinical Supplies & Services (Excl Pass Through)	(1,707)	(1,955)	(247)	(14.5%)	(5,060)	(5,096)	(36)	(0.7%)	(20,238)	(20,238)	0	0.0%
Pass Through(NonPay)	(5,572)	(7,368)	(1,796)	(32.2%)	(19,574)	(20,522)	(948)	(4.8%)	(78,295)	(78,295)	0	0.0%
Drugs (Excl Pass Through)	(1,464)	(958)	507	34.6%	(3,019)	(2,546)	473	15.7%	(12,077)	(12,077)	0	0.0%
Premises and Fixed Plant	(100)	(137)	(37)	(37.1%)	(370)	(447)	(76)	(20.5%)	(1,482)	(1,482)	0	0.0%
Other Non-Pay	(538)	(707)	(169)	(31.3%)	(1,601)	(2,318)	(716)	(44.7%)	(6,404)	(6,404)	0	0.0%
Non-Pay Total	(9,382)	(11,124)	(1,742)	(18.6%)	(29,624)	(30,928)	(1,304)	(4.4%)	(118,495)	(118,495)	0	0.0%
EBITDA	8,379	9,331	951	11.4%	25,126	24,486	(640)	(2.5%)	107,086	107,086	0	0.0%

WTE	IN MONTH 3 Plan	IN MONTH 3 Actual	IN MONTH 3 Variance	IN MONTH 3 Var %
Staff	3,206.8	3,007.1	200	6.2%
NHSP	50.0	162.5	(112)	(224.9%)
Agency	0.6	2.4	(2)	(273.0%)
Total WTE	3,257.5	3,171.9	86	2.6%

Current/YTD Results

The division is reporting a fav variance of £1m in month on a contribution of £9.3m & an adverse YTD variance of £0.6m. In-month position is showing a backdated Q1, comm income activity over performance £1m – mainly relates to Elective work in Cardiology. Excluding pass-through variances, the material YTD issues are:

- Activity ahead of plan EL/DC & OP in Cardiac and Spec Medicine +£1m.
- Private patients over recovery mainly driven by TAVI activity +£0.25m.
- Pay underspends +£3.1m due to vacancies offsetting temporary pay backfill overspend of -£2.5m.
- Industrial action costs -£0.3m Adv.
- Unachieved Pay CIP -£1.6m Adv.
- Unachieved Non-Pay CIP -£0.35m Adv & Other income -£0.288m adv.

YTD CIP target is £1.6m for 2025/26 and £1.1m for 2026/27, totalling £2.7m. The Division has reported delivery of £1.4m YTD.

The Forecast, Management Actions and Risk

Risk – 2026/27 CIP Delivery – Status High

Explanation – annual target is £10.3m for 2026/27 and £6.4m remaining from 2025/26, totalling £16.7m. Currently £7.9m has been identified to deliver this target.

Unmitigated - division has set up divisional CIP board, but the division have identified limited CIP schemes to date on the central tracker and expresses relatively low confidence in full year delivery.

Risk - Future industrial action Status Medium.

Explanation – potential Industrial action for consultant medics regarding pay negotiations.

Mitigation –additional costs per action, no funding centrally confirmed to mitigate.

Risk – High Volume Winter Pressures Status Low.

Explanation – additional capacity required Dec-Feb, and higher costs due to temporary staffing cover, but at low 2025/26 levels.

Mitigation – services to manage budgets seasonally, underspend early part of year to preserve resources for winter.

I&E: Divisional Position NOTSSCAN

Source: Finance Ledger.

Oxford University Hospitals
NHS Foundation Trust

Financial Summary N4NTSS £000s	IN MONTH 3 Plan	Actual	Var £	Var %	YEAR TO DATE Plan	Actual	Var £	Var %	Full Year Plan	Full Year Forecast	Var £	Var %
Activity Income	35,154	36,180	1,025	2.9%	103,786	104,811	1,025	1.0%	424,146	424,146	0	0.0%
Pass Through(Income)	4,361	5,370	1,009	23.1%	16,050	13,896	(2,155)	(13.4%)	64,201	64,201	0	0.0%
PP, Overseas &RTA Income	196	120	(76)	(38.8%)	588	277	(311)	(53.0%)	2,352	2,352	0	0.0%
Other Income	483	518	35	7.3%	1,448	1,505	57	4.0%	5,861	5,861	0	0.0%
Income Total	40,194	42,187	1,993	5.0%	121,872	120,489	(1,383)	(1.1%)	496,559	496,559	0	0.0%
Staff	(20,631)	(20,156)	475	2.3%	(62,292)	(60,521)	1,772	2.8%	(242,451)	(242,451)	0	0.0%
NHSP	(415)	(1,047)	(631)	(152.0%)	(1,318)	(3,248)	(1,929)	(146.3%)	(4,954)	(4,954)	0	0.0%
Agency	(18)	(60)	(42)	(231.3%)	(55)	(174)	(120)	(218.2%)	(219)	(219)	0	0.0%
Pay Total	(21,064)	(21,263)	(199)	(0.9%)	(63,666)	(63,943)	(277)	(0.4%)	(247,624)	(247,624)	0	0.0%
Clinical Supplies & Services (Excl Pass Through)	(3,305)	(3,534)	(230)	(6.9%)	(9,882)	(9,784)	98	1.0%	(39,527)	(39,527)	0	0.0%
Pass Through(NonPay)	(4,361)	(5,370)	(1,009)	(23.1%)	(16,050)	(13,896)	2,155	13.4%	(64,201)	(64,201)	0	0.0%
Drugs (Excl Pass Through)	(2,758)	(1,529)	1,229	44.6%	(5,008)	(4,160)	848	16.9%	(20,032)	(20,032)	0	0.0%
Premises and Fixed Plant	(143)	(125)	17	12.1%	(428)	(338)	90	21.0%	(1,711)	(1,711)	0	0.0%
Other Non-Pay	(1,051)	(1,671)	(620)	(59.0%)	(3,156)	(4,511)	(1,355)	(42.9%)	(12,005)	(12,005)	0	0.0%
Non-Pay Total	(11,617)	(12,229)	(612)	(5.3%)	(34,523)	(32,689)	1,835	5.3%	(137,476)	(137,476)	0	0.0%
EBITDA	7,512	8,695	1,183	15.7%	23,683	23,858	174	0.7%	111,460	111,460	0	0.0%

WTE	IN MONTH 3 Plan	Actual	Variance	Var %
Staff	3,457.7	3,298.9	159	4.6%
NHSP	63.9	164.8	(101)	(157.8%)
Agency	1.0	12.6	(12)	(1,230.5%)
Total WTE	3,522.6	3,476.3	46	1.3%

Current/YTD Results

The division is reporting a favourable variance of £1.2m in month (16% on a contribution of £7.5m) with a small favourable variance of £0.2m YTD (1%). Excluding pass-through variances, the material YTD issues are:

- Aligning activity income to SLAM - £1m Fav
- Industrial action costs - £0.3m Adv
- Pay pressures for SEC and medical staff in Ophthalmology - £0.4m Adv
- Overachieved CIP (inc. 25/26 target) - £0.7m Fav.
- Non-recurrent Non-pay cost pressures - £0.5m Adv
- Private Patient Income underperformance - £0.3m Adv

The division reported £5.2m of CIP delivery YTD against a target of £4.1m. £2.9m of non-recurrent pay and £1.8m of non-pay, including non-recurrent underspends. A further £0.5m was reported for drug gainshare which has not yet flowed into the Trust.

The Forecast, Management Actions and Risk

Risk – 2026/27 CIP Delivery – Status High

Explanation – annual target is £13.4m for 2026/27 and £9.8m remaining from 2025/26, totalling £23.2m. Currently £8m has been identified to deliver this target.

Mitigation - division has set up divisional CIP board, will be meeting on a monthly basis to review schemes/ideas, update the CIP Hopper and ensure EPIDs are completed.

Risk - Future industrial action   Status Medium.

Explanation – consultants have voted in favour of strikes. This presents a risk of activity reduction against plan. Month 2 SLAM suggests overperformance on Variable Elective of £1.0m YTD.

Mitigation –additional costs per action, no funding centrally confirmed to mitigate.

Risk – SEC Capacity   Status Medium.

Explanation – delayed opening reduces activity and performance. 2-3 months delay estimated at 794 electives/day cases, circa £2.3m of income.

Mitigation – alternative sources of capacity being assessed.

I&E: Divisional Position SUWON

Source: Finance Ledger.

Oxford University Hospitals
NHS Foundation Trust

Financial Summary N4SUON	IN MONTH 3				YEAR TO DATE				Full Year	Full Year		
£000s	Plan	Actual	Var £	Var %	Plan	Actual	Var £	Var %	Plan	Forecast	Var £	Var %
Activity Income	37,187	37,857	669	1.8%	102,601	103,270	669	0.7%	412,474	412,474	0	0.0%
Pass Through(Income)	9,642	11,796	2,153	22.3%	27,527	29,443	1,916	7.0%	110,109	110,109	0	0.0%
PP, Overseas &RTA Income	186	164	(22)	(12.1%)	559	501	(58)	(10.4%)	2,237	2,237	0	0.0%
Other Income	938	1,471	533	56.8%	3,132	3,473	341	10.9%	12,529	12,529	0	0.0%
Income Total	47,954	51,287	3,333	7.0%	133,820	136,688	2,868	2.1%	537,350	537,350	0	0.0%
Staff	(18,929)	(17,883)	1,046	5.5%	(56,388)	(53,732)	2,656	4.7%	(220,971)	(220,971)	0	0.0%
NHSP	(98)	(1,234)	(1,135)	(1,155.8%)	(984)	(3,677)	(2,693)	(273.6%)	(3,884)	(3,884)	0	0.0%
Agency	(10)	(23)	(13)	(139.8%)	(49)	(128)	(79)	(160.8%)	(201)	(201)	0	0.0%
Pay Total	(19,037)	(19,140)	(103)	(0.5%)	(57,421)	(57,536)	(116)	(0.2%)	(225,055)	(225,055)	0	0.0%
Clinical Supplies & Services (Excl Pass Through)	(3,976)	(3,901)	75	1.9%	(10,027)	(9,917)	110	1.1%	(40,107)	(40,107)	0	0.0%
Pass Through(NonPay)	(9,642)	(11,796)	(2,153)	(22.3%)	(27,527)	(29,443)	(1,916)	(7.0%)	(110,109)	(110,109)	0	0.0%
Drugs (Excl Pass Through)	(2,930)	(2,693)	237	8.1%	(6,833)	(7,500)	(667)	(9.8%)	(27,334)	(27,334)	0	0.0%
Premises and Fixed Plant	(170)	(162)	8	4.8%	(510)	(517)	(7)	(1.3%)	(2,039)	(2,039)	0	0.0%
Other Non-Pay	(303)	(974)	(671)	(221.0%)	(912)	(2,564)	(1,652)	(181.2%)	(3,836)	(3,836)	0	0.0%
Non-Pay Total	(17,022)	(19,525)	(2,504)	(14.7%)	(45,809)	(49,940)	(4,131)	(9.0%)	(183,424)	(183,424)	0	0.0%
EBITDA	11,896	12,622	726	6.1%	30,591	29,211	(1,379)	(4.5%)	128,870	128,870	0	0.0%

	IN MONTH 3			
WTE	Plan	Actual	Variance	Var %
Staff	3,307.5	3,058.3	249	7.5%
NHSP	49.6	206.7	(157)	(316.5%)
Agency	1.2	5.2	(4)	(338.1%)
Total WTE	3,358.3	3,270.2	88	2.6%

Current/YTD Results

The division is reporting a favorable variance of £0.7m in month (6.1% on a contribution of £11.9m) with an adverse variance of £1.4m YTD. Excluding pass-through variances, the material YTD issues are:

- Activity above plan - £0.7m Fav. (£0.5m Oncology)
- Other income - £0.3m Fav
- Pay underspends – Gross vacancies £4.4m, £2.8m filled with temporary staffing, £1.6m offsetting additional non recurrent CIP delivery
- Industrial action costs - £0.15m Adv. (Pay)
- In tariff drugs activity - £0.7m Adv (£1.2m Adv in Oncology offset with £0.5m in Gastroenterology.
- Underachieved non pay CIP - £1.5m Adv.

YTD CIP target is £0.6m for 2025/26 and £1.8m for 2026/27, totalling £2.4m. The division achieved £3.2m YTD with 41% delivered through non-recurrent means.

The Forecast, Management Actions and Risk

Risk – 2026/27 CIP Delivery – Status High
Explanation – annual target is £12.9m for 2026/27 and £9.3m remaining from 2025/26, totalling £22.2m. This is an increase from M1 CIP target which was ~£15m. Currently £10.4m has been identified to deliver this target in the CIP tracker, however there are a number of other schemes in development that will be added to the tracker in the coming week. *Mitigation* - division has set up divisional CIP board, meeting on a weekly basis to review schemes/ideas, update the CIP Hopper and ensure EPIDs are completed.
Risk - Future industrial action   Status Medium.
Explanation – Any further strikes will increase pay costs and impact on activity. Cost impact in M1 due to strikes was ~£0.15m. There is also a likelihood of some activity reduction creating a risk to the income plan.
Mitigation – Looking to sustain as much activity as possible and carefully monitor strike costs.
Risk – Recruitment to High risk services   Status Medium.
Explanation – current uncovered vacancies are a high risk to patient safety (eg long wait times for radiotherapy). There is recruitment ongoing in these areas which *will increase headcount and pay costs. Mitigation – services being risk assessed to target recruitment by risk profile.*

I&E: Divisional Position CSS

Source: Finance Ledger.

Oxford University Hospitals
NHS Foundation Trust

Financial Summary N4CTDP £000s	IN MONTH 3 Plan	Actual	Var £	Var %	YEAR TO DATE Plan	Actual	Var £	Var %	Full Year Plan	Full Year Forecast	Var £	Var %
Activity Income	10,266	10,752	486	4.7%	29,840	30,325	486	1.6%	120,119	120,119	0	0.0%
Pass Through(Income)	579	348	(231)	(39.9%)	1,648	1,582	(66)	(4.0%)	6,592	6,592	0	0.0%
PP, Overseas &RTA Income	170	116	(54)	(31.6%)	509	410	(99)	(19.4%)	2,036	2,036	0	0.0%
Other Income	1,670	1,693	23	1.4%	4,869	5,111	242	5.0%	19,474	19,474	0	0.0%
Income Total	12,685	12,908	224	1.8%	36,865	37,428	563	1.5%	148,221	148,221	0	0.0%
Staff	(14,761)	(14,625)	135	0.9%	(44,439)	(44,165)	274	0.6%	(173,343)	(173,343)	0	0.0%
NHSP	(164)	(362)	(198)	(120.4%)	(530)	(1,052)	(522)	(98.3%)	(2,038)	(2,038)	0	0.0%
Agency	(27)	2	29	107.8%	(87)	(0)	87	99.9%	(350)	(350)	0	0.0%
Pay Total	(14,952)	(14,985)	(33)	(0.2%)	(45,056)	(45,217)	(161)	(0.4%)	(175,731)	(175,731)	0	0.0%
Clinical Supplies & Services (Excl Pass Through)	(4,095)	(4,221)	(126)	(3.1%)	(12,695)	(11,855)	840	6.6%	(50,672)	(50,672)	0	0.0%
Pass Through(NonPay)	(579)	(348)	231	39.9%	(1,648)	(1,582)	66	4.0%	(6,592)	(6,592)	0	0.0%
Drugs (Excl Pass Through)	(523)	(604)	(81)	(15.5%)	(1,429)	(1,529)	(100)	(7.0%)	(5,714)	(5,714)	0	0.0%
Premises and Fixed Plant	(252)	(83)	169	67.2%	(755)	(527)	229	30.3%	(3,022)	(3,022)	0	0.0%
Other Non-Pay	(522)	(808)	(286)	(54.8%)	(894)	(2,203)	(1,309)	(146.4%)	(2,292)	(2,292)	0	0.0%
Non-Pay Total	(5,971)	(6,064)	(93)	(1.6%)	(17,421)	(17,695)	(274)	(1.6%)	(68,292)	(68,292)	0	0.0%
EBITDA	(8,238)	(8,140)	98	1.2%	(25,612)	(25,484)	128	0.5%	(95,803)	(95,803)	0	0.0%

WTE	IN MONTH 3 Plan	Actual	Variance	Var %
Staff	2,256.1	2,193.7	62	2.8%
NHSP	32.9	55.2	(22)	(67.9%)
Agency	1.4	0.0	1	100.0%
Total WTE	2,290.4	2,248.9	42	1.8%

Current/YTD Results

The Division is reporting breakeven in month (1.2% on a cost of £8.2m) with a breakeven position YTD. Excluding pass-through variances, the material YTD issues are:

- Activity above plan - £0.5m fav. (Radiology +£0.7m).
- Industrial action costs - £0.1m Adv.
- One-off income in Pharmacy/Pathology - £0.13m Fav.
- Underachieved CIP (inc. 25/26 target) - £0.7m Adv.
- Underspend in clinical supplies/drugs - £0.7m Fav.
- CDC increased costs : £0.2m Adv. PET CT Costs : £0.2m Adv

Month 3 CIP target is £1.1m for 2025/26 and £1.7m for 2026/27, totalling £2.79m. The Division achieved £2.23m split equally between recurrent and non-recurrent means.

Activity income has been updated for the 2026/27 SLAM.

The Forecast, Management Actions and Risk

Risk – 2026/27 CIP Delivery – Status High
Explanation – annual target is £11.6m for 2026/27 and £4.4m remaining from 2025/26, totalling £16.0m. Currently £5.8m has been identified to deliver this target (50%)
Mitigation – partial. Division has set up divisional CIP board, will be meeting on a weekly basis to review schemes/ideas, update the CIP Hopper and ensure EPIDs are completed, but reports relatively low confidence.

Risk – Demand Growth Status High.
Explanation – support services (Radiology and Pathology) annually experience circa 5% demand increase leading to cost pressures to deliver capacity. Additional surge demand expected due to more ambitious targets on constitutional KPIs.
Current expenditure budgets have not been funded for growth in 26/27. Internally generated growth remains unfunded, but any additional income is shown in the other clinical divisions, whilst additional sit within CSS.
Mitigation – productivity on resource and demand management required but increases risk on the CIP delivery as an offset. Heightened governance to monitor premium expenditure.

I&E: Divisional Position Non-Clinical Services (inc. Corp, R&D, Estates)

Source: Finance Ledger.

Financial Summary Non-Clinical £000s	IN MONTH 3 Plan	IN MONTH 3 Actual	IN MONTH 3 Var £	IN MONTH 3 Var %	YEAR TO DATE Plan	YEAR TO DATE Actual	YEAR TO DATE Var £	YEAR TO DATE Var %	Full Year Plan	Full Year Forecast	Var £	Var %
Activity Income	26	26	0	0.0%	71	71	0	0.0%	282	282	0	0.0%
Pass Through(Income)	0	0	0	0.0%	0	0	0	0.0%	0	0	0	0.0%
PP, Overseas &RTA Income	343	355	13	3.7%	1,028	793	(235)	(22.8%)	4,113	4,113	0	0.0%
Other Income	11,978	14,905	2,927	24.4%	37,873	37,274	(599)	(1.6%)	145,888	145,888	0	0.0%
Income Total	12,347	15,286	2,939	23.8%	38,972	38,138	(834)	(2.1%)	150,284	150,284	0	0.0%
Staff	(12,143)	(12,538)	(395)	(3.2%)	(36,327)	(35,619)	708	1.9%	(142,699)	(142,699)	0	0.0%
NHSP	(66)	(122)	(56)	(84.8%)	(364)	(355)	9	2.5%	(1,412)	(1,412)	0	0.0%
Agency	(12)	(9)	3	23.5%	(37)	(32)	5	14.5%	(148)	(148)	0	0.0%
Pay Total	(12,222)	(12,670)	(448)	(3.7%)	(36,729)	(36,007)	722	2.0%	(144,260)	(144,260)	0	0.0%
Clinical Supplies & Services (Excl Pass Through)	(385)	(279)	106	27.5%	(1,155)	(803)	352	30.5%	(4,619)	(4,619)	0	0.0%
Pass Through(NonPay)	0	0	0	0.0%	0	0	0	0.0%	0	0	0	0.0%
Drugs (Excl Pass Through)	(42)	(20)	22	52.3%	(126)	(33)	93	73.8%	(505)	(505)	0	0.0%
Premises and Fixed Plant	(14,077)	(13,300)	777	5.5%	(43,900)	(40,625)	3,274	7.5%	(175,927)	(175,927)	0	0.0%
Other Non-Pay	(6,058)	(8,732)	(2,674)	(44.1%)	(19,942)	(20,702)	(760)	(3.8%)	(75,508)	(75,508)	0	0.0%
Non-Pay Total	(20,562)	(22,331)	(1,769)	(8.6%)	(65,123)	(62,163)	2,959	4.5%	(256,559)	(256,559)	0	0.0%
EBITDA	(20,436)	(19,714)	723	3.5%	(62,879)	(60,032)	2,847	4.5%	(250,535)	(250,535)	0	0.0%

WTE	IN MONTH 3 Plan	IN MONTH 3 Actual	IN MONTH 3 Variance	IN MONTH 3 Var %
Staff	1,830.8	1,775.4	55	3.0%
NHSP	19.2	17.0	2	11.6%
Agency	0.9	0.0	1	100.0%
Total WTE	1,850.9	1,792.4	59	3.2%

Current/YTD Results

The combined divisional position is reporting a favourable variance of £0.72m in month (3.5% on a cost of £20.4m) with a favourable variance of £2.8m YTD. The material YTD issues are:

- Estates Utilities (FY impact under review) - £1.4m Fav
- Estates PFI benefits to contract - £0.7m Fav
- Education initial funding vs budget - £1.2m Fav
- SDE capitalisation – Net £0.3m Fav
- Other items - £1.1m Fav primarily timing of spend (e.g. maintenance)
- Unachieved CIP - £1.9m Adv

Month 3 CIP target is £0.5m for 2025/26 and £0.6m for 2026/27, totalling £1.1m. The divisions achieved £0.6m by mainly non-recurrent means.

The WTE budget in month shows a favourable 59 WTE due to the capitalisation of staff in SDE (26) and vacancies held across directorates

The Forecast, Management Actions and Risk

Risk – 2026/27 CIP Delivery – Status High
Explanation – annual target is £10.4m for 2026/27 and £5.2m remaining from 2025/26, totalling £15.6m. Currently only £5.4m has been identified to deliver this target.
Mitigation – a corporate CIP board has been set up to review schemes/ideas, update the CIP Hopper and ensure EPIDs are completed.

Risk – Budget Finalisation Status Low
Explanation – corporate and estates budgets have not been finalised to confirm spending limits for 2026/27. Three directorates flagging as a concern (Strategy, People, Nursing)
Mitigation – following meetings held in May/June final alignment of any items to be confirmed with offset in CIP targets

I&E: Central / Technical

Oxford University Hospitals
NHS Foundation Trust

Financial Summary Technical £000s	IN MONTH 3 Plan	Actual	Var £	Var %	YEAR TO DATE Plan	Actual	Var £	Var %	Full Year Plan	Full Year Forecast	Var £	Var %
Activity Income	(2,134)	(1,491)	643	30.1%	3,259	4,631	1,372	42.1%	16,572	16,572	0	0.0%
Pass Through(Income)	396	472	77	19.4%	0	0	0	0.0%	0	0	0	0.0%
PP, Overseas &RTA Income	110	0	(110)	(100.0%)	329	0	(329)	(100.0%)	1,442	1,442	0	0.0%
Other Income	461	44	(417)	(90.5%)	901	277	(623)	(69.2%)	3,534	3,534	0	0.0%
Income Total	(1,168)	(975)	193	16.6%	4,489	4,908	420	9.4%	21,548	21,548	0	0.0%
Staff	2,091	(96)	(2,187)	(104.6%)	4,239	123	(4,116)	(97.1%)	31,631	31,631	0	0.0%
NHSP	(2,267)	0	2,267	100.0%	(5,847)	0	5,847	100.0%	(23,258)	(23,258)	0	0.0%
Agency	(164)	0	164	100.0%	(588)	(91)	497	84.5%	(1,977)	(1,977)	0	0.0%
Pay Total	(339)	(96)	243	71.6%	(2,197)	32	2,228	101.4%	6,396	6,396	0	0.0%
Clinical Supplies & Services (Excl Pass Through)	2,110	319	(1,791)	(84.9%)	6,700	0	(6,700)	(100.0%)	23,075	23,075	0	0.0%
Pass Through(NonPay)	(396)	(472)	(77)	(19.4%)	0	(0)	(0)	0.0%	0	0	0	0.0%
Drugs (Excl Pass Through)	2,307	153	(2,154)	(93.4%)	1,378	(0)	(1,378)	(100.0%)	5,188	5,188	0	0.0%
Premises and Fixed Plant	5,454	4,765	(689)	(12.6%)	17,918	14,161	(3,757)	(21.0%)	71,776	71,776	0	0.0%
Other Non-Pay	(2,377)	711	3,088	129.9%	(8,295)	705	9,001	108.5%	(22,864)	(22,864)	0	0.0%
Non-Pay Total	7,099	5,476	(1,623)	(22.9%)	17,701	14,866	(2,834)	(16.0%)	77,175	77,175	0	0.0%
EBITDA	5,592	4,405	(1,187)	(21.2%)	19,993	19,806	(186)	(0.9%)	105,119	105,119	0	0.0%
Capital and Financial Charges	(8,614)	(9,017)	(403)	(4.7%)	(26,694)	(27,341)	(648)	(2.4%)	(106,149)	(106,149)	0	0.0%
Control Total	(3,022)	(4,612)	(1,590)	(52.6%)	(6,701)	(7,535)	(834)	(12.4%)	(1,030)	(1,030)	0	0.0%

WTE	IN MONTH 3 Plan	Actual	Variance	Var %
Staff	65.4	18.2	47	72.3%
NHSP	0.7	0.0	1	100.0%
Agency	0.3	0.0	0	100.0%
Total WTE	66.5	18.2	48	72.7%

Current/YTD Results

The combined divisional position is reporting an adverse variance of £1.6m in month and £0.9m YTD. The key YTD issues are:

- Commissioning income - £1.4m Fav
- Finances charges - £0.4m Adv
- Central CIP unachieved - £7.8m Adv (driven by non-pay)
- Central Reserves - £3.1m Fav linked to Fav variance for WTE
- Alignment to external plan - £2.6m Fav

Commissioning Income – In Month 3 clinical income in the ledger was updated to match the SLAM contract values. The remaining activity income in reserves is the Q1 pay awards awaiting contract inclusion (and updated activity pricing). The month 3 over performance is also included in reserves.

The Forecast, Management Actions and Risk

Risk – 2026/27 CIP Delivery – Status High
Explanation – annual target is £61.8m for 2026/27 is being held centrally, covering the £33.0m non-recurrent and £28.8m strategic CIP targets. These have been assigned to Chief officers with only £15.5m (25%) identified.
Mitigation – the PMO is currently driving identification of CIP schemes to deliver against these targets. This is being mitigated in the short term through elective income overperformance and non-recurrent/technical benefits

Risk – SEC Delivery – Status High
Explanation – a risk that the implementation of SEC delivers lower income or higher costs, overall leading to a financial pressure. Estimates were made as part of the business case which need validating.
Mitigation – plan for the September opening being costed and grounded in specialty level plans.

Risk – Reserves Reconciliation to Plan– Status High
Explanation – budgets set later than plan, more realistic and localised. Leads to differences in the allocation of costs between plan and budget in central reserves.
Mitigation – change being developed to remove the central reserve and update the plan with NHSE.

Drivers: Cost Improvement Programme (CIP)

Source: CIP Tracker. The table shows the 2026/27 planned CIP targets submitted to NHSE

Savings Summary £000s	IN MONTH 3 Plan	IN MONTH 3 Actual	IN MONTH 3 Var £	IN MONTH 3 Var %	YEAR TO DATE Plan	YEAR TO DATE Total Actual	YEAR TO DATE Var £	YEAR TO DATE Var %	Full Year Plan	Full Year Identified (inc Delivered YTD)	Full Year Var £	Full Year Var %
MRC	476	884	408	86%	1,130	1,382	252	22%	10,313	7,017	(3,296)	(32%)
NOTSSCAN	681	1,653	972	143%	1,695	5,224	3,529	208%	13,463	10,807	(2,656)	(20%)
SUWON	690	1,236	546	79%	1,775	2,249	474	27%	12,856	7,585	(5,271)	(41%)
CSS	643	616	(26)	(4%)	1,680	2,065	385	23%	11,613	6,517	(5,096)	(44%)
Corporate	350	218	(131)	(38%)	941	468	(473)	(50%)	5,896	2,791	(3,106)	(53%)
Estates	315	357	42	13%	927	669	(259)	(28%)	4,042	2,985	(1,057)	(26%)
Education	14	0	(14)	(100%)	24	0	(24)	(100%)	440	0	(440)	(100%)
Operational Services	18	4	(13)	(76%)	38	4	(34)	(89%)	430	262	(168)	(39%)
Operating Expenses	0	0	0	0%	0	0	0	0%	0	0	0	0%
Central - NR CIP	2,752	435	(2,317)	(84%)	8,256	1,776	(6,480)	(78%)	33,025	11,323	(21,703)	(66%)
Central - Strategic CIP	840	0	(840)	(100%)	1,351	0	(1,351)	(100%)	28,772	4,094	(24,679)	(86%)
2025/26 FYE	987	987	0	0%	3,033	3,033	0	0%	6,016	6,016	0	0%
Total	7,308	6,394	(914)	(12.5%)	19,302	16,877	(2,425)	(12.6%)	126,866	59,423	(67,443)	(53.2%)

Please be aware that the CIP plan considers all items as recurrent, with the exception of the Central NR line listed in the table above.

PFR - Identified Trustwide View (£'000) **59,423**
YTD Delivered + Remaining Year Identified *Total identified*

Status Profile

Risk Profile	Total Target: 126,866	Fully Developed	Plans in Progress	Opportunity	Unidentified	
	Low	34,921 28%	612 0%	- 0%		35,555 28%
	Medium	7,253 6%	2,192 2%	1,242 1%		10,691 8%
	High	2,006 2%	1,007 1%	10,164 8%	67,470 53%	80,620 64%
		44,201 35%	3,817 3%	11,405 9%	67,443 53%	

Overall Position

The Trust has a total new 2026/27 CIP requirement of c.£120.8m, underpinning delivery of the financial plan and £6.1m of full year effect from 2025/26, totalling £126.9m. As at Month 3, identified schemes total £59.4m, leaving £67.4m (c.53%) unidentified. Risk/status profile is summarised in the matrix to the left.

Identification and Pipeline Development

There has been a material increase in identified CIP week-on-week, driven primarily by non-recurrent items. Weekly CIP meetings are in place to drive savings identification and achieve a fully developed programme. Divisional pipelines remain in development, with schemes continuing to be validated and progressed through governance into fully developed schemes (EPIDs).

Performance YTD

Reported delivery in Month 3 is below plan (£0.9m), reflecting timing lag between scheme identification and reliance on non-recurrent savings to deliver planned savings.

2025/26 CIP Targets

£28.7m of recurrent unachieved CIP remains from 2025/26 within service budgets. This remains a source of risk to a sustainable financial position.

Cash





	2026	2027		
	M12	M01	M02	M03
Debtor Days	6.07	8.20	7.89	8.20
Creditor Days	38.72	34.61	35.56	24.62

Month 3 Cash Position

Cash is above plan at Month 3 by £3.6m at £7.2m.

- Capital creditors from year end have now all been paid and the balance has returned to be close to plan
- Balance is marginally higher than plan due to in-year 26/27 capital spend being behind plan, this is timing and not a permanent difference

The cash plan for 2026/27 indicates that cash pressures are expected to return over the Summer months and alignment to plan including cash-releasing CIPs are essential to managing the cash position for the remainder of 26/27.

Cash Forecast – monthly detail will be available in the Reading Room prior to the Board meeting

The NED Finance meeting will review management actions underway to manage the cash position

Capital



Capital Expenditure £m	IN MONTH 03 Plan	IN MONTH 03 Actual	IN MONTH 03 Variance	YEAR TO DATE Plan	YEAR TO DATE Actual	YEAR TO DATE Variance	Full year Plan
Surgical Elective Centre (SEC)	-	0.1	(0.1)	-	0.3	(0.3)	22.2
Estates Safety/CIR	2.0	0.3	1.6	5.9	1.3	4.5	22.8
Estates PFI lifecycling	1.0	1.0	0.0	2.9	2.9	0.0	11.4
UEC Level 1	2.5	0.1	2.4	7.5	0.6	6.9	7.5
Helipad	0.6	-	0.6	1.7	0.0	1.7	6.8
Other Estates	0.0	0.1	(0.1)	0.1	0.5	(0.4)	1.4
Diagnostics	-	1.6	(1.6)	3.7	1.8	1.9	3.7
Equipment	0.1	0.4	(0.3)	0.3	0.5	(0.1)	1.8
Digital	0.1	0.5	(0.4)	0.2	1.5	(1.3)	1.8
Divisional Priorities	-	-	-	-	-	-	0.4
Contingency/(Oversubscription)	-	-	-	-	-	-	-
Gross Capital Expenditure	**6.2**	**4.1**	**2.0**	**22.1**	**9.4**	**12.8**	**79.6**
Sales, disposals, and other deductions	-	(0.0)	0.0	-	(0.0)	0.0	(9.7)
Nat Capital Expenditure	**6.2**	**4.1**	**2.1**	**22.1**	**9.3**	**12.8**	**69.9**

Capital Expenditure - by funding source £m	IN MONTH 03 Plan	IN MONTH 03 Actual	IN MONTH 03 Variance	YEAR TO DATE Plan	YEAR TO DATE Actual	YEAR TO DATE Variance	Full year Plan
Operational Capital	4.3	1.1	3.2	16.5	4.3	12.1	41.7
National Funding PDC	0.3	-	0.3	0.9	-	0.9	9.0
Other Capital Expenditure (G&D, PFI)	1.6	3.0	(1.4)	4.8	5.0	(0.2)	19.2
Net Capital Expenditure	**6.2**	**4.1**	**2.1**	**22.1**	**9.3**	**12.8**	**69.9**
Add back sales, disposals, and other deductions	-	0.0	(0.0)	-	0.0	(0.0)	9.7
Gross Capital Expenditure	**6.2**	**4.1**	**2.0**	**22.1**	**9.4**	**12.8**	**79.6**

Capital Plan 2026/27

- The capital plan aligns with the third plan submission (April 2026), unchanged from the February submission.
- It includes a plan for Operational Capital of £41.7m and initial provision of £9.0m of National PDC funding (Estates Safety), along with provisions for G&D and PFI life-cycling.

Overall Position at 30 June 2026 – M03

- Gross CapEx to June was £9.4m against a plan of £22.1m.
- Overall synopsis: slower than planned expenditure on prior-year overruns, although some expenditure to date relates to new business, due mostly to HRB checks. Some cost pressures realized from prior year require mitigatory measures in the forward delivery plan.
- Significant variances

  UEC Level 1 £6.9m under plan. Delayed start due to HRB checks. Impact on FOT, none at present. Impact on cash flow, right-shift of in-year cash outflow profile.

  Estates Safety/CIR £4.5m under plan. Main cause: delayed start in Maternity due to HRB checks and late confirmation of funding awards. Impact on FOT, none at present. Impact on cash flow, right-shift of in-year cash outflow profile.

  Diagnostics £1.9m under plan. Main cause (£3.7m): delayed BiPlane, now expected later in year, due to HRB checks. Impact on FOT, none at present. Impact on cash flow, none (RoU contract). Now partly offset (£1.6m) by recognition of PFI addition not in plan. Impact on FOT, n/a, PFI excluded from control total. Impact on cash flow, none, part of PFI UP.

  Helipad £1.7m under plan. Cause: project delay to address affordability and technical issues, Impact on FOT, n/a, G&D excluded from control total. Impact on cash flow, none (charitably funded).

  Digital £1.3m over plan. Main cause: actual includes £0.8m of capitalisation of SDE costs in line with prior year treatment, but omitted from capital plan. Impact on FOT, around £3.3m extrapolated pressure if continuing. Impact on cash flow, none overall – offset by revenue.
- Forecast in graphic is to plan from July

Appendices

Appendix 1: Driver - Cost Expenditure Run-Rates

Source: Finance Ledger.





Pay Trends

Total pay was £0.3m higher in June compared to May. Excluding R&D, pay costs were £0.7m lower in June than in May.
Total substantive staffing costs were £0.5m higher in June compared to May. Excluding R&D, substantive pay reduced by £0.5m.
Temporary staff in-month expenditure was £0.2m lower in June compared to May, with bank costs decreasing by £0.2m and agency costs unchanged.

WTEs overall decreased by 86 in month at 13,978 (excluding R&D, WTE decreased by 91). Substantive staff decreased by 54 WTE in June, while bank staff decreased by 33 WTE and agency staff decreased by 4 WTE. Pronounced reductions in temporary staffing have been seen in prior years particularly in March 2024.



Non-Pay Trends

Total non-pay is £9.0m higher in June than in May.

Excluding R&D, non-pay costs are £8.2m higher than last month. Excluding passthrough costs that are £6.5m higher than in May (inc. 2 patients at £4.2m for Hemgenix), non-pay costs are £1.7m higher in June.

This is predominantly on other expenditure which was £2.2m higher in June, of which £1.7m relates to HIOTV (offset by additional HIOTV income). HIOTV executed a grant transaction where income was received by the Trust as its host and then immediately paid out to other parties.

Appendix 2: Driver - Financial Sustainability, Underlying Position

Source: Finance Ledger.

Month 3 Year to Date (£ms) Plan	Underlying	R&D	Pass through	One-off	Reported
Income	367.7	13.0	64.8	0.1	445.3
Pay	(251.5)	(9.5)	0.0	(1.3)	(259.6)
Non pay	(113.0)	(2.9)	(64.8)	(5.9)	(174.8)
Non-Opex	(26.8)	0.0	0.0	(0.1)	(26.7)
Total Plan	**(23.5)**	**0.6**	**(0.0)**	**(7.1)**	**(15.8)**

Actuals	Underlying	R&D	Pass through	One-off	Reported
Income	371.2	12.3	65.4	0.1	448.9
Pay	(255.6)	(9.7)	0.0	(6.8)	(258.5)
Non pay	(115.5)	(2.1)	(65.4)	(4.4)	(178.5)
Non-Opex	(27.3)	0.0	0.0	0.0	(27.3)
Total Actuals	**(27.2)**	**0.5**	**(0.0)**	**(11.2)**	**(15.5)**

Variance	Underlying	R&D	Pass through	One-off	Reported
Income	3.5	(0.6)	0.6	(0.1)	3.6
Pay	(4.1)	(0.3)	0.0	(5.5)	1.1
Non pay	(2.5)	0.9	(0.6)	1.4	(3.7)
Non-Opex	(0.6)	0.0	0.0	0.1	(0.6)
Total Variance	**(3.7)**	**(0.1)**	**0.0**	**(4.0)**	**0.3**

Income & Expenditure – Adjusted Run Rate Performance (£m) Surplus/(Deficit)



Month 3 YTD underlying performance was £27.2m, and £3.7m worst than planned, driven by more of the efficiency savings made being non-recurrent YTD ..

One-off: The more significant non-recurrent items included in the reported financial position to date for this financial year include:

- Estates benefits in PFI (£1.6m)
- PFI deductions of (£1.3m).
- Industrial action net impact (£0.7m).
- Dropping the Flowers accrual (£0.5m).
- Non-recurrent pay savings (~£3m)

There is an opportunity for divisions to convert non-recurrent pay savings into recurrent savings by reviewing establishments and removing posts permanently. Divisions are being given support to do this.

Strategic CIPs, while slow to mobilise, should also have a positive effect in Q4 as they will have a full year effect far greater than their in-year benefits.

However, even with these actions the Trust is likely to miss its target to reduce the underlying deficit by c£40m.

R&D:
- £0.1m off plan year to date.
- Small mix change between pay and non-pay due to specific grants won and projects/trials delivered.

Pass through:
- Passthrough income and expenditure are above plan by £0.6m year to date, net nil impact.
- The Trust is paid 3+ months in arrears for over-performance and after suppliers have been paid.

Appendix 3: Driver - Activity Income

Oxford University Hospitals
NHS Foundation Trust

Source: SLAM.

API Types updated2	API Types updated	IN MONTH 3 Budget	IN MONTH 3 Actual	IN MONTH 3 Variance	IN MONTH 3 Var %	YEAR TO DATE Budget	YEAR TO DATE Actual	YEAR TO DATE Variance	YEAR TO DATE Var %
Variable - Elective	DC	7,433	7,272	-161.3	-2.2%	22,300	22,292	-7.9	0.0%
	EL	9,576	11,334	1,758.6	18.4%	28,727	31,324	2,597.6	9.0%
	Excess Bed	77	88	11.2	14.6%	231	264	32.5	14.0%
	OPFA	6,743	6,845	102.6	1.5%	20,228	20,525	297.4	1.5%
	Outpatients	3,602	4,159	556.9	15.5%	10,805	12,350	1,544.4	14.3%
Variable - Elective Total		**27,430**	**29,698**	**2,268.0**	**8.3%**	**82,290**	**86,754**	**4,464.0**	**5.4%**
Variable - Other		**2,864**	**3,167**	**302.9**	**10.6%**	**12,130**	**12,999**	**869.0**	**7.2%**
Blended Payments	UEC	29,956	29,846	-110.1	-0.4%	89,867	89,490	-377.3	-0.4%
	Rad Blended	1,232	1,243	10.3	0.8%	3,697	3,726	28.8	0.8%
Blended Payments Total		**31,188**	**31,088**	**-99.8**	**-0.3%**	**93,564**	**93,216**	**-348.5**	**-0.4%**
Passthrough	Variable - Devices	4,753	5,228	474.8	10.0%	14,259	15,095	835.9	5.9%
	Variable - Drugs	16,847	20,510	3,663.2	21.7%	50,540	50,347	-192.7	-0.4%
Passthrough Total		**21,600**	**25,738**	**4,138.0**	**19.2%**	**64,799**	**65,442**	**643.2**	**1.0%**
Fixed	Fixed - Devices	27	27	0.0	0.0%	80	80	0.0	0.0%
	BLOCK - HCD	2,326	2,326	0.0	0.0%	6,978	6,978	0.0	0.0%
	Fixed	44,351	43,951	-400.0	-0.9%	131,283	130,883	-400.0	-0.3%
Fixed Total		**46,703**	**46,303**	**-400.0**	**-0.9%**	**138,342**	**137,942**	**-400.0**	**-0.3%**
Grand Total		129,786	135,995	6,209.1	4.8%	391,126	396,353	5,227.6	1.3%

Commissioning income: a new process that more directly links activity data within SLAM to income reported in the ledger, has been implemented for M3 reporting. However, as the SLAM finalisation process does not dovetail with the monthly financial reporting timeline, the M3 position reflects M1 & 2 SLAM, extrapolated forward. There are still 2 contracts which have not been agreed for 2026/27, but the OUH is caught in an allocation dispute between ICBs about the disaggregation of funding previously allocated to Frimley ICB (value at risk £2m).

'Elective Variable' and 'Variable Other' activity will be paid at 100% of tariff. Overperformance against plan to date has resulted in overachievement of income against the YTD plan.

Passthrough Drugs and Devices will be reimbursed in full by commissioners, as long as they have been prescribed in line with agreed commissioning policies. In June 2 patients were administered Hemgenix blood factor products, of over £2m each, causing the large performance in-month.

UEC and Radiotherapy activity is subject to a 'Blended payment' approach in 2026-27. Activity above or below agreed plans is subject to a marginal payment or clawback of 20% of tariff for UEC, and 50% for Radiotherapy. The ledger reflects the position after the marginal rates have been applied. UEC activity is currently significantly under plan, but the marginal rate means the Trust keep 80% of the tariff for activity below the plan.

Appendix 4: Statement of Financial Position (SOFP)

Oxford University Hospitals
NHS Foundation Trust

Statement of Financial Position 2024/25	M12 2025	In Month 3 2026	In Mth PLAN	Variance to PLAN	Movement in month	Movement from year-end
NON-CURRENT ASSETS:						
Property, Plant and Equipment	£841.1	£834.1	£851.5	(£17.4)	(£1.5)	(£7.0)
Investments	£64.2	£64.2	£62.7	£1.5	£0.0	£0.0
Trade and Other Receivables - non current	£26.4	£29.0	£23.3	£5.8	£0.1	£2.7
Total Non Current Assets	**£931.6**	**£927.3**	**£937.5**	**(£10.1)**	**(£1.4)**	**(£4.3)**
CURRENT ASSETS:						
Inventories	£32.9	£32.8	£32.6	£0.2	(£0.7)	(£0.1)
Trade and Other Receivables - current	£90.5	£105.0	£103.1	£1.9	£23.7	£14.5
Cash	£75.9	£7.2	£3.6	£3.6	(£31.0)	(£68.7)
Total Current Assets	**£199.2**	**£145.0**	**£139.2**	**£5.7**	**(£8.0)**	**(£54.3)**
TOTAL ASSETS	**£1,130.9**	**£1,072.3**	**£1,076.7**	**(£4.4)**	**(£9.4)**	**(£58.5)**
CURRENT LIABILITIES						
Trade and Other Payables - current	(£219.2)	(£178.7)	(£206.5)	£27.8	£6.8	£40.5
Other Liabilities: Deferred Income - current	(£2.9)	(£3.5)	(£9.6)	£6.1	(£0.2)	(£0.5)
Other Liabilities: - current	(£0.4)	(£0.4)	(£0.3)	(£0.1)	(£0.0)	(£0.0)
Provisions current	(£0.8)	(£0.8)	(£0.5)	(£0.3)	£0.0	£0.0
Borrowings - current	(£11.6)	(£10.4)	(£12.6)	£2.2	(£3.6)	£1.2
Loans - current	(£1.4)	(£1.3)	(£1.6)	£0.3	(£0.0)	£0.0
Total Current Liabilities	**(£236.4)**	**(£195.1)**	**(£231.1)**	**£36.0**	**£2.9**	**£41.3**
NET CURRENT ASSETS/(LIABILITIES)	**(£37.2)**	**(£50.2)**	**(£91.9)**	**£41.7**	**(£5.1)**	**(£13.0)**
TOTAL ASSETS LESS CURRENT LIABILITIES	**£894.5**	**£877.2**	**£845.6**	**£31.6**	**(£6.5)**	**(£17.3)**
NON-CURRENT LIABILITIES:						
Other Liabilities: Deferred Income - non current	(£3.7)	(£3.7)	(£2.3)	(£1.4)	£0.0	£0.0
Other Liabilities: - non current	(£4.0)	(£4.0)	(£3.4)	(£0.6)	(£0.1)	£0.0
Provisions - non current	(£6.9)	(£6.9)	(£6.4)	(£0.5)	£0.0	£0.0
Borrowings - non current	(£399.3)	(£397.9)	(£393.8)	(£4.1)	£4.6	£1.4
Loans - non current	(£16.5)	(£16.0)	(£16.3)	£0.3	£0.2	£0.5
Total Non-Current Liabilities	**(£430.3)**	**(£428.4)**	**(£422.2)**	**(£6.2)**	**£4.7**	**£1.9**
TS LESS LIABILITIES (Total Assets Employed)	**£464.1**	**£448.8**	**£423.4**	**£25.4**	**(£1.8)**	**(£15.4)**
TAXPAYERS EQUITY						
Public Dividend Capital	£426.8	£426.8	£394.8	£31.9	£0.0	£0.0
Retained Earnings reserve	(£138.1)	(£150.5)	(£149.2)	(£1.2)	(£0.8)	(£12.4)
Revaluation Reserve	£183.6	£180.6	£181.4	(£0.8)	(£1.0)	(£3.0)
Other Reserves	£1.7	£1.7	£1.7	£0.0	£0.0	£0.0
Merger Reserve	£0.0	£0.0	£4.5	(£4.5)	£0.0	£0.0
FV Assets Reserve	(£9.9)	(£9.9)	(£9.9)	£0.0	£0.0	£0.0
Total	**£464.1**	**£448.8**	**£423.4**	**£25.4**	**(£1.8)**	**(£15.4)**

Balance Sheet

- PPE has reduced YTD due to additions being lower than depreciation and amortisation
- A PFI debtor has been recognised at a larger amount than was anticipated at the time the plan was produced
- Receivables are slightly higher than plan due to timing of billing and receipt of cash
- Cash is above plan – see earlier slide
- Trade and other payables are lower than plan due to timing of month end supplier BACS runs